Skip to main content
Elsevier

Receptor Tyrosine Kinases

  • 1st Edition, Volume 147 - June 24, 2020
  • Latest edition
  • Editors: Rakesh Kumar, Paul B. Fisher
  • Language: English

Receptor Tyrosine Kinases, Volume 147 in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research in the ar… Read more

Data Mining & ML

Unlock the cutting edge

Up to 20% on trusted resources. Build expertise with data mining, ML methods.

Explore now

Description

Receptor Tyrosine Kinases, Volume 147 in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research in the area of Receptor Tyrosine Kinases (RTKs) in the context of major basic science and translational advances, their importance in the development of a large number of anti-cancer drugs over the decades, and a peek into postulated advances in the coming decades for a number of RTK. Chapters in this new release are contributed by a group of International leading scientists who have a rich history in this field.

Key features

  • Provides the latest information on core advances in receptor tyrosine kinases in cancer research
  • Offers outstanding and original reviews on a range of cancer research topics by leading authorities in the field
  • Serves as an indispensable reference for faculty, researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology

Table of contents

Contributions from:Yosef Yarden, Ph.D., Weizmann Institute of Science, ISRAELRakesh Kumar, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIAPaul Fisher, M.D., Ph.D., Virginia Commonwealth University, School of Medicine, USAMark Moasser, M.D., University of California San Francisco, USA William J. Muller, Ph.D., McGill University, CANADA Ravi Salgia, M.D., Ph.D., City of Hope's Comprehensive Cancer Center, USARenata Pasqualini, Ph.D., Rutgers NJ School of Medicine, USAFernanda Staquicini, Ph.D., Rutgers NJ School of Medicine, USAM. Radhakrishna Pillai, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIAMien-Chie Hung, Ph.D., China Medical University, TAIWANE. Prem Reddy, Ph.D., Mount Sanai School of Medicine, USADoug Yee, M.D., Masonic Cancer Center University of Minnesota, USANandini Verma, Ph.D.,　Advanced Centre for Treatment, Research and Education in Cancer,　Mumbai, INDIA　Masakazu Toi, M.D., Ph.D., Kyoto University School of Medicine, JAPANLouis Chow, M.D., UNIMED Medical Institute, Hong Kong, CHINALuis Marques da Costa, M.D., Ph.D., University of Lisbon School of Medicine, PORTUGAL

Product details

  • Edition: 1
  • Latest edition
  • Volume: 147
  • Published: June 24, 2020
  • Language: English

About the editors

RK

Rakesh Kumar

Rakesh Kumar acquired qualifications of Environment Science and Engineering from IIT Bombay in 1987. He then pursued work on developing technologies for automobile pollution control, which also led to a Ph.D.in Environment Engineering. Dr. Kumar's experience includes a wide range of environment science and engineering field, such as: Air Pollution Control and Management, Water and Wastewater Treatment, Hazardous & Municipal Waste Management, Environmental Impact Assessment and Environmental Audit and Climate Change.
Affiliations and expertise
Director, CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nehru Marg, Nagpur, Maharashtra, India

PF

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Cellular, Molecular and Genetic Medicine, VCU Institute of Molecular Medicine, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, United States

View book on ScienceDirect

Read Receptor Tyrosine Kinases on ScienceDirect